Last edition
News about "Cycle Pharmaceuticals "
Cycle Pharma Selects Forma Life Sciences for US Supply of FDA-Approved CAVHANZA
Cycle Pharmaceuticals selects Forma Life Sciences to establish US commercial supply of Food and Drug Administration (FDA)-approved CAVHANZA (nilotinib) for Philadelphia chromosome-positive CML patients.
Cycle Pharmaceuticals | 13/08/2026 | By News Bureau | 112
Cycle Pharmaceuticals to Acquire Applied Therapeutics
The acquisition positions Cycle Pharmaceuticals to strengthen its rare disease portfolio, adding Applied Therapeutics’ promising CNS-penetrant aldose reductase inhibitor, govorestat, which targets severe unmet needs in central nervous system metabolic disorders.
Cycle Pharmaceuticals | 12/12/2025 | By Akanki | 240
Cycle Pharma Acquires Banner Life Sciences
BAFIERTAM will become Cycle’s second branded product for the treatment of MS alongside TASCENSO ODT® (fingolimod).
Cycle Pharmaceuticals | 14/01/2025 | By Aishwarya | 1148
Cycle Pharmaceuticals Offers All-Cash Proposal to Acquire Vanda Pharmaceuticals
Cycle Pharmaceuticals Ltd. has confirmed that it proposed to the Board of Directors of Vanda Pharmaceuticals, Inc. to acquire 100 percent of Vanda’s issued and outstanding shares for a cash consideration of USD 8.00 per Vanda share.
Cycle Pharmaceuticals | 07/06/2024 | By Aishwarya | 999
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy